10 completed. 10 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 10 |
| Phase 1 | 2 | Completed 2 |
Follow Immunosuppression: new trials by email Literature Review of Immunosuppression trials Research Report on Immunosuppression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations NVX-CoV2372 - Immunosuppression, COVID-19 | Phase 2 | Completed | University of Wisconsin, Madison | 21 | 2023-11-20 | 2025-10-20 |
| NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia Thymoglobulin, Fludarabine, Cyclophosphamide - Severe Aplastic Anemia, Aplastic Anemia | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 21 | 2016-09-01 | 2022-07-12 |
| Extracorporeal Photopheresis in Liver Transplantation. Phase II Clinical Trial in Safety and Efficacy in Patients With Gradual Decrease of Immunosuppression. Extracorporeal Photopheresis Procedure (FEC) - Liver Transplantation, Immunosuppression | Phase 1 / Phase 2 | Completed | Red de Terapia Celular | 10 | 2013-04-01 | 2017-03-30 |
| Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients Immunosuppression withdrawal - Liver Transplant Recipients, Liver Transplantation | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 161 | 2012-08-14 | 2019-10-07 |
| TBE-vaccine to Patients With Rheumatoid Arthritis Who Are Using Immunosuppressive Drugs TBE-vaccine, Vaccination against TBE - Rheumatoid Arthritis, Exposed to TBE-virus | Phase 2 | Completed | Sormland County Council, Sweden | 68 | 2010-05-01 | 2011-05-25 |
| Safety and Efficacy of an Inactivated and Non Adjuvanted Vaccine Against Influenza A in Renal Transplant Recipients inactivated non adjuvanted pandemic H1N1 vaccine - Renal Transplant Recipients, Immunosuppression | Phase 2 | Completed | Institut National de la Santé Et de la Recherche Médicale, France | 122 | 2009-11-01 | 2026-02-19 |
| Cholesterol and Fatty Acid Synthesis in Islet and Liver Transplant Patients and Effect of Dietary Intervention Dietary intervention - supplements - Immunosuppression, Hyperlipidemias | Phase 1 / Phase 2 | Completed | University of Alberta | 46 | 2005-11-01 | 2009-07-28 |
| Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis Daclizumab - Anterior Uveitis, Arthritis, Juvenile Idiopathic | Phase 2 | Completed | National Eye Institute (NEI) | 6 | 2005-08-01 | 2017-01-30 |
| Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients Alemtuzumab, Tacrolimus, Mycophenolate mofetil - Kidney Failure, Chronic, Kidney Transplantation | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 35 | 2005-01-01 | 2017-01-02 |
| Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignances SOLEX 300i Stem Cell Selection - Immunosuppression, Leukemia | Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 70 | 2002-01-23 | 2019-12-16 |
Anemia, Aplastic (1) · Arthritis, Juvenile (1) · Arthritis, Rheumatoid (1) · Bone Marrow Failure Disorders (1) · COVID-19 (1) · Diabetes Mellitus, Type 1 (1) · Graft vs Host Disease (1) · Hyperlipidemias (1) · Iritis (1) · Kidney Failure, Chronic (1) · Leukemia (1) · Neoplasms, Plasma Cell (1) · Renal Insufficiency (1) · Uveitis, Anterior (1)
Immune System Diseases (4) · Autoimmune Diseases (3) · Arthritis (2) · Connective Tissue Diseases (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Joint Diseases (2) · Musculoskeletal Diseases (2) · Rheumatic Diseases (2) · Skin and Connective Tissue Diseases (2) · Anemia (1) · Bone Marrow Diseases (1) · Chronic Disease (1) · Coronaviridae Infections (1) · Coronavirus Infections (1)
Mycophenolic Acid (2) · Tacrolimus (2) · Alemtuzumab (1) · Antilymphocyte Serum (1) · Cyclophosphamide (1) · Daclizumab (1) · FEC protocol (1) · NVX-CoV2373 adjuvated lipid nanoparticle (1) · Sirolimus (1) · Whole-Body Irradiation (1) · fludarabine (1) · fludarabine phosphate (1) · thymoglobulin (1)
National Institute of Allergy and Infectious Diseases (NIAID) (2) · Institut National de la Santé Et de la Recherche Médicale, France (1) · National Eye Institute (NEI) (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Red de Terapia Celular (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Sormland County Council, Sweden (1) · University of Alberta (1) · University of Wisconsin, Madison (1)
United States (6) · Canada (2) · Finland (1) · France (1) · Spain (1) · Sweden (1)
A. John Barrett, M.D. (1) · Amy E DeZern, MD (1) · Freddy Caldera, DO, MS (1) · J Bucuvalas, M.D. (1) · Lars Rombo, MD Professor (1) · Michael T Clandinin, PhD (1) · S Feng, M.D., Ph.D. (1) · William Harmon, MD (1)
PMID 19664754, PMID 22052056, PMID 23065508, PMID 23103195, PMID 23524640, PMID 32343796, PMID 32786149, PMID 33280227, PMID 35819312, PMID 37084383
2009 (1), U01AI100807 (1)